Calypso to collaborate with Philips and IMPAC

TriMed Staff | | Health Imaging | Diagnostic Imaging
Calypso Medical Technologies Inc. signed strategic collaboration agreements with Philips Medical Systems' Radiation Oncology division and IMPAC Medical Systems at the 46th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Oct. 3 - 7, in Atlanta. Calypso intends to collaborate with both companies on future product offerings.

Philips expects to provide enhancements to its treatment planning systems with target localization data from the Calypso 4D Localization System. According to Keith Tipton, general manager, Phillips Radiation Oncology Systems, "Calypso's unique technology, in conjunction with the Pinnacle³ and AcQSim treatment planning and simulation systems from Philips, has the potential to deliver on the promise of adaptive and image-guided radiation therapy."

IMPAC intends to integrate target localization data generated from the Calypso 4D Localization System into its electronic medical record (EMR) which currently streamlines treatment setup, verification, and recording of linear accelerators. "By introducing the technology to IMPAC's large installed base along with new accelerator installations, the potential exists to accelerate the adoption of adaptive therapy," said IMPAC President and CEO Joseph Jachinowski.

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup